13th to 15th
Two pharmaceutical giants
First on the list is GlaxoSmithKline (NYSE:GSK), which, together with Sanofi (NASDAQ:SNY), is developing an adjuvanted vaccine (that means it contains an ingredient to help achieve better immune response) targeting SARS-CoV-2.
Today, let us look at two companies investigating SARS-CoV-2 vaccines in current or upcoming clinical trials, and determine which one is a better buy.
Image source: Getty Images.
The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.
After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Pfizer Inc.
RNA vaccines use a different approach that takes advantage of the process that cells use to make proteins: cells use DNA as the template to make messenger RNA (mRNA) molecules, which are then translated to build proteins.
Default Partners, MSN, Repeatable, usmf-health-care, Yahoo News
Interested in Learning More?
Article Analysis is at the foundation of powerful media monitoring and insights. Learn what you can build with powerful curated search engines, real-time listening and trend analysis on the topics, markets and companies critical to your organization.